Marker Therapeutics, INC 8-K filings

Marker Therapeutics, Inc. announced that its stockholders approved an amendment to increase authorized common stock from 30 million to 130 million shares at the 2026 Annual Meeting.

Marker Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held on May 1, 2026, establishing a new deadline for shareholder proposals.

Marker Therapeutics announced encouraging clinical data for its lead MT-601 program in lymphoma, alongside Q3 2025 financial results and an extended cash runway.

Marker Therapeutics strengthens its Board of Directors with the appointment of biopharma executive Kathryn Penkus Corzo, effective November 1, 2025.

Marker Therapeutics announced the treatment of the first patient in its Off-the-Shelf (OTS) program for Multi-Antigen Recognizing (MAR)-T cell therapy, showing encouraging preliminary safety data.

Marker Therapeutics announced encouraging Phase 1 APOLLO study results for MT-601 in relapsed lymphoma, showing high objective response rates and a favorable safety profile.

Marker Therapeutics, Inc. announced a change in its independent registered public accounting firm from Marcum LLP to CBIZ CPAs P.C., effective August 6, 2025.

Marker Therapeutics, Inc. announced a strategic collaboration with Cellipont Bioservices for the cGMP manufacturing of its lead Multi-Antigen Recognizing (MAR)-T cell therapy, MT-601, to support its APOLLO study and future commercial readiness.

Marker Therapeutics, Inc. announced that its stockholders approved all three proposals at the 2025 Annual Meeting, including the election of four directors, advisory approval of executive compensation, and ratification of Marcum LLP as the independent auditor.

Marker Therapeutics announces preliminary data from its Phase 1 APOLLO study showing that lymphodepletion enhances the expansion and persistence of MT-601 MAR-T cells in lymphoma patients.

Marker Therapeutics announced its year-end 2024 financial results and provided corporate updates, emphasizing the advancement of its MT-601 program and strategic financing initiatives.

Marker Therapeutics stockholders approved the issuance of warrants to acquire common stock at a Special Meeting held on March 21, 2025.

Marker Therapeutics files an amendment to its previous 8-K report to correct the grant dates of stock options awarded to the CEO and non-employee directors.

Marker Therapeutics approved stock option awards for its CEO and non-employee directors on February 12, 2024.

John Wilson resigned from the Board of Directors of Marker Therapeutics, Inc. effective January 24, 2025.

Marker Therapeutics, Inc. successfully closed a private placement, raising approximately $16.1 million to support general corporate purposes and working capital.

Marker Therapeutics has announced a $16.1 million private placement to support the clinical advancement of its MT-601 lymphoma treatment, which has shown promising early results in a Phase 1 study.

Marker Therapeutics has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support clinical trials of its MT-601 therapy for pancreatic cancer.

Marker Therapeutics announced its third quarter 2024 financial results, highlighted by progress in its MT-601 clinical trials and the receipt of two NIH grants totaling $4 million.

Marker Therapeutics announced encouraging preliminary results from its Phase 1 APOLLO study of MT-601 in lymphoma patients and secured a $2 million NIH grant.

Marker Therapeutics has been awarded a $2 million grant from the National Institutes of Health to advance clinical trials of its MT-601 therapy for non-Hodgkin's lymphoma patients who have relapsed after CAR T-cell treatment.

Marker Therapeutics held its 2024 Annual Meeting of Stockholders, electing directors and ratifying the accounting firm, and subsequently terminated its $75 million at-the-market offering agreement.

Marker Therapeutics announced encouraging preliminary results from its Phase 1 APOLLO study of MT-601 in lymphoma patients, along with its first quarter 2024 financial results.

Marker Therapeutics announced that clinical data from their APOLLO study, showcasing durable responses to MT-601 in lymphoma patients, was presented at the 11th Global Summit on Hematologic Malignancies.

Marker Therapeutics announced positive clinical results for its lead lymphoma program, secured non-dilutive funding, and implemented strategic cost-saving measures.

Marker Therapeutics has terminated its $25 million share purchase agreement with Lincoln Park Capital, citing a sufficient financial runway through the fourth quarter of 2025.

Marker Therapeutics has signed a Master Services Agreement with Cell Ready, a CDMO owned by a company director, to manufacture GMP drug product for its MT-401 and MT-601 therapies.